This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Pegylated Recombinant Human Arginase I
- DrugBank Accession Number
- DB16282
- Background
Pegylated Recombinant Human Arginase I is under investigation in clinical trial NCT03455140 (A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Pegylated recombinant human arginase i bct-100
- External IDs
- BCT-100
- RH-ARG1-PEG-5,000 MW
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Pegylated Recombinant Human Arginase I is combined with Cinchocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S3HC6XX81X
- CAS number
- 1433787-75-7
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Hepatocellular Carcinoma 2 2 Unknown Status Treatment Acute Myeloid Leukemia 1 1 Completed Treatment Adenocarcinoma of Prostate / Melanoma 1 1 Completed Treatment Hepatocellular Carcinoma / Neoplasm 1 1 Terminated Treatment Leukemias / Lymphoma 1 1, 2 Completed Treatment Acute Lymphocytic Leukemia, Pediatric / Acute Myeloid Leukemia, Childhood / Cancer / Childhood Solid Neoplasm 1 1, 2 Completed Treatment Hepatocellular Carcinoma / Neoplasm 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 15, 2020 18:17 / Updated at December 20, 2020 03:40